Emtricitabine-Tenofovir Disoproxil Fumarate and Acid-Base Changes
Tenofovir disoproxil fumarate (TDF) combined with emtricitabine can cause proximal renal tubular dysfunction leading to metabolic acidosis, specifically type 2 (proximal) renal tubular acidosis (RTA), though this is uncommon. The primary mechanism involves mitochondrial toxicity in renal tubular cells, resulting in impaired bicarbonate reabsorption and phosphate wasting 1.
Mechanism and Clinical Presentation
The acid-base disturbance occurs through TDF-induced proximal tubulopathy (Fanconi syndrome), which manifests as:
- Metabolic acidosis with normal anion gap (hyperchloremic acidosis)
- Urinary bicarbonate wasting
- Hypophosphatemia
- Hypokalemia
- Glucosuria (despite normal serum glucose)
- Proteinuria
In severe cases, lactic acidosis can develop due to mitochondrial damage in hepatocytes and muscle cells, particularly when TDF levels are elevated 2. This represents a more serious complication with higher morbidity risk.
Risk Factors Requiring Enhanced Vigilance
Certain populations face substantially higher risk and warrant closer monitoring:
- Low body weight patients (increased drug exposure per kilogram) 2
- Concurrent use of pharmacokinetic boosters (ritonavir or cobicistat), which increase tenofovir concentrations by 20-40% 3, 4
- Pre-existing renal impairment (creatinine clearance <60 mL/min) 5, 1
- Concomitant nephrotoxic medications or hepatitis C treatment regimens containing sofosbuvir/ledipasvir 3
- Older age (>50 years) or diabetes/hypertension 6
Monitoring Protocol
Before Initiating TDF/FTC:
- Confirm creatinine clearance ≥60 mL/min using Cockcroft-Gault formula 5
- Baseline serum creatinine, phosphate, and bicarbonate
- Urinalysis for glucose and protein 5
During Treatment:
Check serum creatinine and calculate creatinine clearance at 3 months after initiation, then every 6 months while on therapy 5, 1. For high-risk patients (those with boosters, low body weight, or borderline renal function), monitor every 3 months 1, 6.
Additional monitoring should include:
- Serum phosphate and bicarbonate every 6 months
- Urinalysis for glucosuria and proteinuria if proximal tubulopathy suspected
- Serum lactate if symptoms develop (nausea, diffuse myalgia, unexplained fatigue) 2
Warning Signs Requiring Immediate Evaluation:
- Progressive decline in creatinine clearance
- New-onset hypophosphatemia (<2.5 mg/dL)
- Serum bicarbonate <20 mEq/L
- Unexplained muscle pain, weakness, or nausea 2
Management of Acid-Base Disturbances
If proximal tubulopathy or metabolic acidosis develops, immediately switch from TDF to tenofovir alafenamide (TAF) or to a regimen without tenofovir (such as dolutegravir/lamivudine) 1. TAF achieves therapeutic intracellular concentrations with 90% lower plasma tenofovir exposure, dramatically reducing nephrotoxicity risk 3.
For established proximal RTA:
- Discontinue TDF immediately
- Switch to TAF-based regimen or dolutegravir/lamivudine 1
- Provide bicarbonate supplementation if serum bicarbonate <18 mEq/L
- Replace phosphate and potassium as needed
- Monitor for resolution over 4-12 weeks after TDF discontinuation
For severe lactic acidosis (lactate >5 mmol/L, pH <7.2):
- Discontinue all antiretrovirals immediately
- Provide intensive supportive care
- Consider hemodialysis for severe cases 2
- Do not rechallenge with TDF
Critical Pitfall to Avoid
Do not continue TDF when creatinine clearance falls below 50 mL/min 1. While dose adjustment is theoretically possible, the risk of accumulation and toxicity is substantial. Switch to TAF (if creatinine clearance >30 mL/min) or a non-tenofovir regimen 1.
The combination of TDF with cobicistat or ritonavir-boosted protease inhibitors requires particular caution, as these agents increase tenofovir exposure by inhibiting renal tubular secretion 3, 4. Frequent renal monitoring (every 3 months) is mandatory when these combinations cannot be avoided 3.